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Hematopoietic stem cell transplantation is the treatment of choice for many hematologic diseases,
such as multiple myeloma, bone marrow aplasia and leukemia. Human leukocyte antigen (HLA)
compatibility is an important tool to prevent post-transplant complications such as graft rejection and
graft-versus-host disease, but the high rates of relapse limit the survival of transplant patients.
Natural Killer cells, a type of lymphocyte that is a key element in the defense against tumor cells, cells
infected with viruses and intracellular microbes, have different receptors on their surfaces that
regulate their cytotoxicity. Killer immunoglobulin-like receptors are the most important, interacting
consistently with human leukocyte antigen  class I molecules present in other cells and thus controlling
the activation of natural killer cells. Several studies have shown that certain combinations of killer
immunoglobulin-like receptors and human leukocyte antigens (in both donors and recipients) can
affect the chances of survival of transplant patients, particularly in relation to the graft-versus-
leukemia effect, which may be associated to decreased relapse rates in certain groups. This review
aims to shed light on the mechanisms and effects of killer immunoglobulin-like receptors - human
leukocyte antigen  associations and their implications following hematopoietic stem cell transplantation,
and to critically analyze the results obtained by the studies presented herein.
Keywords: Hematopoietic stem cell/transplantation; Histocompatibility testing; Receptor KIR/
immunology; HLA antigens; Killer cells, natural; Graft vs host disease.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice
for many hematologic diseases. However, chronic graft-versus-host disease (GvHD) and
relapse are still the main obstacles to the success of this therapy.
Currently, a number of possible interventions are being studied in different parts of
the world to reduce these problems. The use of Natural Killer (NK) cells is one such
alternative because there is the possibility of leukemic cell lysis by NK cells from the donor.
These studies may lead to important changes in the strategy of selecting unrelated
donors in HSCT, thereby increasing not only the survival of transplant recipients, but also
providing an improved quality of life of patients after transplantation.
Natural Killer cells
NK cells were characterized over 30 years ago as a cytotoxic effector of the innate
immune system. Recognized as a subtype of lymphocytes that have cytoplasmic granulation,
NK cells are larger than conventional lymphocytes and are found in the peripheral circulation
and in various tissues and organs such as the bone marrow, spleen, lymph nodes, liver,
intestine and placenta. Approximately 15% of all circulating lymphocytes are NK cells,(1)
and these constitute the first line of defense against pathogens such as intracellular bacteria,
parasites and, in particular, viruses, in addition to preventing the formation of tumors. They
act by releasing cytokines or by lysis of the target cell. Many of these substances initiate
and maintain adaptive immune responses; cell lysis is mediated by apoptosis involving
granule exocytosis (perforin and granzymes) and Fas/FasL (Fas Ligand) binding.(2)
Recent studies have increased our understanding of how NK cells recognize target
cells. The response of these cells is intimately involved in the interaction with Human
leukocyte antigen (HLA) class I molecules present on target cells. Two large families of NK
cell surface receptors have been identified – CD94/NKG2 and killer immunoglobulin-like
receptors (KIRs).(3) As KIRs are highly polymorphic and interact with a larger number of
HLA class I molecules, they have become extremely important in studies on susceptibility
to infections, on HSCT and on cancer.
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The group of KIR genes comprises a region of
approximately 150 Kb in the leukocyte receptor complex (LRC)
on chromosome 19q13.4. KIRs are members of a group of
regulatory molecules on the surface of NK cells, in subgroups
of Tγδ+ lymphocytes, effector Tαß+ lymphocytes and
memory lymphocytes.(4)
The KIR family includes activating and inhibitory
molecules. Inhibitory KIRs (2DL and 3DL) have a long
cytoplasmic tail containing tyrosine-based inhibitory motifs
(ITIMs) that trigger inhibitory events of cytotoxicity. In
contrast, activating KIRs (2DS and 3DS) interact with the
DAP12 molecule, which has tyrosine-based activation motifs
(ITAMs) that cause a cascade that results in an increase in
cytoplasmic granulation and the production of cytokines and
chemokines, thereby initiating immune response.(5)
KIRs are the main functional regulators of NK cells.
The balance between activation and inhibition of NK cells
occurs through the binding of KIRs with HLA class I
molecules present in all nucleated cells of an individual. The
different forms of these receptors are specific to certain HLA
molecules and some of these KIR-ligand pairs are already
known. The KIR2DL4, for example, specificity binds to the
HLA-G molecule,(6) while the KIR3DL1 receptor binds to a
subset of HLA molecules with the Bw4 epitope, present in
approximately one third of all HLA-B molecules. The
KIR3DS1 is highly homologous with 3DL1 and seems to share
the Bw4 epitope as ligand, although this needs to be
experimentally verified. The KIR3DL2 receptor is still being
discussed, but studies suggest that HLA-A3 and HLA-A11
perform this role.(7)
Most KIRs bind to HLA-C molecules. It is worth
remembering the importance of the dimorphism of amino
acids, such as residue 80 of α-helix-1, in the definition of
this HLA receptor. On this basis, HLA-C alleles may be
defined as "Group 1" or "Group 2". The KIR2DL2, 2DL3
and 2DS2 - HLA-C*01, *03, *07 and *08 alleles are included
in "Group 1". And "Group 2" consists in the KIR2DL1 and
2DS1 - HLA-C*02, *04, *05 and *06 alleles.(8) Finally,
evidence suggests that HLA-CW4 is a receptor for
KIR2DS4.(9)
Allogeneic hematopoietic stem cell transplantation
Allogeneic HSCT is the treatment of choice for many
hematologic diseases. The outcome of HSCT is dependent
on several factors which include disease stage at the time of
transplant, the conditioning regimen, source of cells, the
degree of HLA matching between donor and recipient and
the development of chronic GvHD. Recent studies have
indicated that other potential factors could also influence
the course of the transplant.(10-12)
The first attempts to investigate the role of NK cells in
HSCT were carried out in haploidentical transplants (only
one compatible HLA haplotype). The results of haploidentical
transplants in the early 1990s were disappointing mainly due
to the high incidence of mortality, often caused by alloreactive
T cells of the donor against recipient (often leading to fatal
GvHD) or recipient against donor (rejection). The introduction
of concepts such as ‘missing self’ by NK cells in the clinical
practice has led to innovative approaches in the treatment of
hematologic malignancies.(13)
Killer immunoglobulin-like receptors and haploidentical
hematopoietic stem cell transplantation
The chance that a donor presents a HLA combination
identical to a sibling recipient is 25%. In many cases, there is
no compatibility in the family and an unrelated donor is not
always found. In this situation it is possible to perform HSCT
with a family member who has only one identical HLA
haplotype (haploidentical). Thus, this partial compatibility
can be found in both parents and in 50% of siblings. In
haploidentical transplantation, the presence of T cells in the
graft means strong reactivity of these cells against the
alloantigens of the recipient. Alternatively, T-cell depletion
reduces graft-versus-host reactions, but allows a higher
incidence of leukemic relapse due to a reduced graft-versus-
leukemia effect.(14) In theory, NK cells present in the graft
might overcome this lack of alloreactivity of the graft against
leukemia, as long as they are not inhibited by their
corresponding HLA ligands in the recipient.
One of the first studies that evaluated the alloreactivity
effect of NK cells by KIR-HLA mismatch in HSCT involving
haploidentical pairs enrolled 60 patients with acute
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML)
and chronic myeloid leukemia (CML).(15) The presence of HLA
incompatibility may favor both graft versus host and host
versus graft alloreactivity mediated by T cells. Thus, T cell
depletion was performed. The results showed that patients
with myeloid leukemias suffered alloreactivity of NK cells
from the donor, following the rules of KIR-HLA mismatch.
This study brought to light a new aspect of haploidentical
HSCT: lysis of residual leukemic cells in the recipient by
allogeneic NK cells.
For a more comprehensive investigation of this effect,
the same group increased the number of patients in a new
study and included models of NK cell alloreactivity in mice.(16)
Thirty-four haploidentical transplants with KIR-HLA
mismatches and 58 KIR-HLA matched haploidentical
transplants were analyzed. In AML patients, transplantation
with alloreactive NK cells fully protected the group against
rejection, GvHD and leukemic relapse. The probability of
disease-free survival at 5 years was 60% in this group in
contrast to 5% in the group without alloreactivity. Multivariate
analysis, which considered the conditioning regimen, the
number of hematopoietic stem cells and T cells in the graft
and disease stage at transplantation, showed that graft versus
host KIR-HLA incompatibility was an independent factor for
increased survival. This effect was not observed in ALL
patients.
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From these observations, alloreactive NK cells were
infused into mice previously conditioned to develop human
AML. The mice that received non-alloreactive NK cells died
within three weeks. However, those that received NK cells
with KIR-HLA mismatches survived until the day of sacrifice
(120 days). These observations showed that the alloreactivity
generated by NK cells is associated with a marked graft-
versus-leukemia effect, and a total control of rejection. Other
data suggest that alloreactive NK cells accelerate the
elimination of antigen-presenting cells (APCs) from bone
marrow, spleen and intestine, suggesting a mechanism that
prevents GvHD by the elimination of APCs.
Contradictory results were demonstrated for 62 patients
who also received haploidentical donor grafts.(17) It was found
that the alloreactivity of NK cells was associated with a high
incidence of GvHD. What both studies emphasized was the
difference in pre-transplant protocols. The contradictory
results of these two studies may be related to the lack of T
cell depletion in recipients or by the presence of a significantly
greater number of these cells in the graft received by patients
in one study(17) compared to the other.(16) Thus, the beneficial
role of NK cell alloreactivity may be masked by the presence
of T cells, suggesting that the effects of the KIR-HLA
mismatch depend on specific conditioning protocols.
Experimentally, some authors demonstrated that the
infusion of haploidentical donor NK cells, in patients who
received conditioning regimens with high doses of
cyclosporine and fludarabine, was associated with
increased levels of IL-15, essential in the final differentiation
of CD34+ hematopoietic stem cells into NK cells.(18)
Furthermore, there was a higher rate of complete remission
in these patients, especially those receiving infusions of
NK cells with KIR-HLA mismatches, and possibly presenting
a graft-versus-leukemia effect.
In a study, which analyzed 137 patients with severe
combined immunodeficiency (SCID), 124 received
haploidentical HSCT.(19) SCID is a fatal genetic disorder that
combines lymphopenia with the absence of T cells,
increasing susceptibility to infection. Although the
incidence and severity of GvHD were not different, analysis
of survival at five years showed that the HLA-KIR mismatch
might favor survival but without statistical significance. The
authors suggested that NK cell alloreactivity may not play
a fundamental role in HSCT of patients with SCID.
Another study evaluated 109 AML patients, 57
patients reported in 2002 and over 52 since then.(20) When
the alloreactivity of NK cells was considered, event free
survival was better for remission patients and even for
relapsed patients. The study demonstrated that this strategy
not only prevents GvHD, but also provides a pronounced
graft-versus-leukemia effect that significantly increases the
survival of transplanted patients. According to the authors,
alloreactivity of NK cells from the donor against the recipient
emerges as a crucial factor in promoting improved survival
in haploidentical HSCT.
If incorporated as a selection criterion, the chance of
finding a donor with alloreactive NK cells rises from 33% to
49%,(21) which would represent a substantial gain for
recipients. Another advantage is the increased availability of
haploidentical donor relatives may reduce delay to transplant.
Killer immunoglobulin-like receptors and related
hematopoietic stem cell transplantation
The ideal for patients who require HSCT donors is to
find an HLA identical relative. This type of transplantation
usually provides quick engraftment, a decreased rate of GvHD
and greater success in immune reconstitution. As the chance
of finding an HLA identical related donor is 25% in the clinical
practice about three quarters of recipients will need
haploidentical transplantations or transplants using volunteer
donors.(21)
In 2004, one study carried out KIR-HLA genotyping of
220 related HLA identical donor-recipient pairs (112 for
myeloid diseases and 108 lymphoid diseases).(22) For patients
with myeloid diseases, survival was lower in those
homozygous for Group 2 (C2) HLA-C compared to patients
with Group 1 (C1). This effect was observed only when the
donor had the KIR2DS2 gene. As KIR2DS2 is in strong linkage
disequilibrium with KIR2DL2 (receptor inhibited by C1), this
would indirectly indicate lower survival in patients who do
not have the receptor for KIR2DL2, an opposite result to the
model in which this lack of inhibition would result in NK cell
alloreactivity with a consequent elimination of residual
leukemic cells.(23)
In 178 patients with AML, CML, ALL and primary
myelodysplastic syndrome (MDS) who received HSCT with T
cell depletion from HLA-identical related donors, some authors
observed that the disease-free survival was significantly higher
in patients with AML and MDS that did not have the HLA
ligand for the inhibitory KIR of the donor.(24) Moreover, the
relapse rate was lower in these individuals, which may be related
to higher survival rates. The results differ from a study in which
T cell depletion was not performed.(22)
In another study(25) involving 83 patients with different
types of hematologic malignancies who received HSCT from
related HLA-identical donors without T cell depletion, a high
relapse rate was found when high numbers of activating KIRs
were present in both the patient and donor. According to the
authors, a consequence of this finding may be an increased
alloreactivity of the host against graft, impairing the response
of donor cells resulting in an insufficient graft-versus-leukemia
effect and increased risk of leukemic relapse.
Killer immunoglobulin-like receptors and unrelated
hematopoietic stem cell transplantation
Patients in need of HSCT who do not have an HLA-
identical donor in the family may benefit from unrelated HLA
compatible donors. The advent of high resolution HLA
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genotyping and the identification of new alleles, as well as
advances in the prevention and treatment of GvHD have
improved the survival rate of transplanted patients.
Consequently, Registers of volunteer bone marrow donors
have been organized in several countries. In 2010, the number
of volunteer donors on the register in Brazil was approximately
1,400,000. (26)
The role of the KIR-HLA mismatch in unrelated donors
was first explored in 2002 in a study that examined 175
unrelated pairs with one HLA mismatch at the class I locus.(27)
The groups, divided between those with or without KIR-
HLA mismatches, included patients with different
hematological diseases. The most intriguing result was that
in patients with myeloid disease characteristics, the five-year
survival was lower in the KIR-HLA mismatch group.
The advantage of the alloreactivity of NK cells was
re-confirmed in a study of unrelated donors.(28) Conditioning
was standard, including T-cell depletion using ATG (anti-
thymocyte immunoglobulin). The disease-free survival of
KIR-HLA mismatch patients was significantly higher
compared to patients without mismatches. The benefit was
even greater when patients with myeloid diseases were
analyzed separately, none had leukemic relapse or died of
transplant-related complications. Due to the potent
immunosuppression provided by ATG, engraftment may have
been improved, and consequently a more rapid recovery of
alloreactive NK cells of the graft may have occurred.
Contradictory results were presented by a later study
of patients with AML, CML and MDS who received either
partially matched HLA grafts or from unrelated HLA-identical
donors.(29) An increased likelihood of leukemic relapse was
found for recipients with HLA-KIR mismatches. In response
to these findings, some differences between the two studies
must be mentioned, such as the mean age of patients, the
conditioning protocols and the stem cell source. The first
used predominantly peripheral hematopoietic stem cells and
the mean age of patients was higher, indicating an advanced
stage of disease in these recipients, favoring leukemic relapse.
In 2005, a study evaluated 374 patients with myeloid
leukemia and found decreased rates of leukemic relapse in
donor-recipient pairs with KIR-HLA mismatches however graft
failure rates were higher.(30) There were no significant differences
in disease-free survival or transplant-related mortality.
Another group, in an analysis of 104 patients who were
submitted to HSCT with unrelated donors, found increased
rates of rejection in patients with alloreactive NK cells against
the graft, due to lysis of donor cells by the recipient’s NK
cells.(31) Acute Grade III and IV GvHD was more frequent in
transplants with KIR-HLA mismatches, a result similar to
other studies involving protocols without extensive T cell
depletion. Interestingly, the presence of a high number of
activating or inhibitory KIR genes in donors had a protective
effect against GvHD and gave a higher survival rate.
Two large retrospective multicenter studies were then
performed. In the first, which enrolled 1770 patients, there
was a decreased leukemic relapse rate in recipients with KIR-
HLA mismatches.(32) The second, however, found that, in an
analysis involving 1571 recipients, incompatibility is
disadvantageous.(33) Contradictory results may occur in
surveys of this size; these are very heterogeneous studies
with differences in conditioning protocols, immunosuppression
and transplantation techniques.
Most studies conducted on HSCT focus on the effect
of the lack of inhibitory KIRs by their HLA class I pair, and
the role of activating KIRs remains largely undefined. The
results of a study in 2006 of 25 patients who received unrelated
donor HSCT (23 HLA identical) showed a higher mortality
risk and incidence of GvHD when the gene for the activating
receptor, KIR2DS2, was present in the donor. The presence
of KIR2DS2 might increase the alloreactivity of donor cells
(especially for certain subgroups of T cells that express KIRs)
and result in severe GvHD.(34)
Conclusions
It is noteworthy that many studies did not perform KIR
genotyping, but used an algorithm to predict KIR-HLA
mismatches. Not always the presence of the corresponding
HLA ligand means inhibition as the KIR gene may be absent.
Another factor that may be related to the survival of these
patients is the presence of activating KIRs, which is
information only available from genotyping. High resolution
sequencing of KIR genes is also proving useful to identify
the real alleles involved in the rejection process, GvHD and
relapse, all factors that affect survival rates.
More recent studies have been developed to establish
trials that can provide information regarding to the
alloreactivity of 'donor-recipient' pairs, such as NK cell
crossmatch, which, by means of serological testing, can check
the possibility of leukemic cell lysis by donor NK cells.(35)
These studies may lead to important changes in the unrelated
donor selection strategy for hematopoietic stem cell
transplantation, in an attempt not only to increase survival
of transplant recipients and but also to provide a better quality
of life for patients after HSCT.
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